Waldenstrom Macroglobulinemia (WM) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Waldenstrom Macroglobulinemia Emerging Therapy and TPP Insights

Thelansis's "Waldenstrom Macroglobulinemia (WM) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Waldenstrom Macroglobulinemia Overview

Waldenstrom macroglobulinemia (WM) is a rare B-cell malignancy classified as lymphoplasmacytic lymphoma, characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that secrete monoclonal immunoglobulin M (IgM). Some patients remain asymptomatic and can be monitored without immediate therapy, whereas symptomatic disease may cause anemia, fatigue, lymphadenopathy, constitutional symptoms, peripheral neuropathy, or other IgM-mediated complications. Hyperviscosity syndrome is a serious manifestation of elevated IgM and may cause visual, neurological, and bleeding abnormalities requiring urgent plasma exchange. Treatment is generally reserved for symptomatic disease and may include rituximab-based chemoimmunotherapy, proteasome inhibitor combinations, or Bruton tyrosine kinase (BTK) inhibitors such as zanubrutinib. MYD88 and CXCR4 mutation status can help guide treatment selection. Despite prolonged disease control with modern therapies, relapse remains common, sustaining the need for more durable and well-tolerated treatment strategies.

Key Highlights

• In Germany, WM prevalent cases are projected to increase from 5,035 in 2026 to 5,256 by 2036.
• Waldenstrom Macroglobulinemia (WM) is a rare, slow-growing blood cancer affecting B lymphocytes.
• Disease progression and complications, including anemia and increased blood viscosity, can affect patient outcomes.
• Unmet need remains for treatments offering durable disease control with improved tolerability.

Market Overview

• The France WM market is projected to grow from $11M in 2026 to $16M by 2036.
• Market growth is driven by:
• Increasing use of targeted therapies
• Continued development of novel treatment approaches
• Future growth will depend on therapies that improve long-term disease control and patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Janssen Pharmaceutical K.K.
• Ascentage Pharma Group Inc.
• Janssen Research & Development, LLC
• AbbVie
• Cellectar Biosciences, Inc.
• BeOne Medicines
• BeiGene
• Acerta Pharma BV
• Loxo Oncology, Inc.
• Newave Pharmaceutical Inc.
• Carna Biosciences, Inc.
• Eli Lilly and Company
• Guangzhou Lupeng Pharmaceutical Company LTD.
• Merck Sharp & Dohme LLC
• Nurix Therapeutics, Inc.